During treatment with Ipilimumab, patients should be especially aware of the serious adverse effects it may cause and the potential risks associated with treatment. While the drug can significantly improve the immune response, it can also cause immune-mediated side effects, particularly severe immune-mediated diseases, transfusion-related reactions, and embryo-fetal toxicity. In order to ensure a smooth treatment of the patient, careful monitoring and necessary adjustments are required during the treatment.

Precautions for Ipilimumab(Yervoy)

Severe and fatal immune-mediated adverse reactions

Ipilimumab is a fully human monoclonal antibody that blocks the CTLA-4 pathway-induced T cell inhibitory signaling and eliminates the inhibitory effect on the immune response. This drug may induce immune-mediated adverse effects, including, but not limited to, immune-mediated colitis, immune-mediated hepatitis, immune-mediated skin diseases, immune-mediated endocrine disorders (such as adrenal insufficiency, hyperthyroidism, hypothyroidism, thyroiditis, type 1 diabetes, and hypophysitis), immune-mediated pneumonia, immune-mediated nephritis with renal dysfunction, and various other immune-mediated adverse effects.

Infusion-related reactions

Serious infusion-related reactions may occur with Ipilimumab. Ipilimumab should be discontinued in patients who have a severe or life-threatening infusion reaction. Patients with mild or moderate infusion reactions should be slowed or slowed down in the infusion.

Analysis of postoperative complications of Ipilimumab after allogeneic hematopoietic stem cell transplantation

Fatal or severe graft-versus-host disease (GVHD) can occur in patients treated with Ipilimumab before or after allogeneic hematopoietic stem cell transplantation (HSCT), and these complications can occur even with intervention between allogeneic HSCT and CTLA-4 receptor-blocking antibodies.

Patients are closely followed for evidence of GVHD and intervened in a timely manner. Consider the benefits and risks of treatment with Ipilimumab after allogeneic HSCT.

Embryo-fetal toxicity

Based on the mechanism of action and the results of animal studies, Ipilimumab may cause harm to the fetus when given to pregnant women. Inform pregnant women of potential risks to the fetus. Women of childbearing potential are advised to use effective contraception during Ipilimumab treatment and for 3 months after the last dos.

Risks associated with combination administration with nivolumab

Ipilimumab is indicated in combination with nivolumab in patients with advanced RCC, MSI-H or dMMR mCRC, HCC and NSCLC. See the full prescribing information for nivolumab for additional risk information applicable to combination therapy.